Expiration date: 07/2025

Structure and Composition:

Drops eye 0.4%. 1 ml contains:

oxybuprocaine 4 mg

Other ingredients: benzalkonium chloride, purified water

in dark glass bottles with a dropper or in vials-droppers of 5 ml plastic bundle in a cardboard one bottle.

Description pharmaceutical form:

Colorless transparent liquid.

Pharmacokinetics:

Inokain easily penetrates the corneal stroma after a single instillation into conjunctival its cavity. Over the next 15 minutes there is a quantitative decrease in stromal concentration of the drug, resulting in a 12-15 minute period of anesthesia with a single instillation.

Description of the pharmacological actions:

Local anesthetic blocks the nerve endings. It penetrates the tissue at a local appointment. Compared to tetracaine and other local anesthetics has less irritating effect on the conjunctiva and cornea.

Surface anesthesia of the conjunctiva and cornea occurs after 30 seconds and lasts for 15 minutes.

Clinical Pharmacology:

0.4% Inokain solution widely used in ophthalmology because after instillation into the eyes quickly causes surface anesthesia, it has little irritating effect on the conjunctiva, well into the epithelium and virtually no damaging influence on him.

Indications:

Local anesthesia in ophthalmology:

• measurement of intraocular pressure (tonometry)
  
• Gonioscopy
  
• diagnostic scraping of the conjunctiva
  
• extraction of foreign bodies and sutures from the cornea and conjunctiva
  
• short surgery the cornea and conjunctiva.
  

Contraindications:

Individual hypersensitivity to the drug.

Application of pregnancy and breastfeeding:

Sufficient experience of use of the drug during pregnancy and breastfeeding is not. Can be used for its intended purpose of the attending physician, if the expected therapeutic effect is greater than the risk of possible side effects.

Side effect:

Short tingling burning and redness of the conjunctiva keratitis, allergic reactions (rare).

Drug Interactions:

Not described in the literature negative or positive effects simultaneous introduction into the conjunctival cavity oxybuprocaine and other conventionally used eye drops.

It is noted that oxybuprocaine can theoretically reduce the antibacterial activity of sulfonamides.

Dosage and administration:

Locally, instilled into the conjunctival sac of 1 drop. Duration of anesthesia (up to 1 hour) provides Inokaina instillation three times at intervals of 4-5 minutes.

Overdose:

Data for drug overdose absent.

Precautionary measures:

Sufficient experience of use in children is not the drug. Can be used for its intended purpose of the attending physician, if the expected therapeutic effect is greater than the risk of possible side effects.

Special instructions:

Only applicable for instillation into the conjunctival sac. Do not use for injection.

Prolonged, repeated and prolonged use (as well as other local anesthetics) may lead to a stable corneal clouding.

Not intended for long-term therapy in complex treatment of diseases of the eye.

During anesthesia is necessary to protect the eyes from irritating chemical effects, foreign bodies and friction.

Storage conditions:

(Do not freeze).